KONINKLIJKE PHILIPS NV (PHI1.DE) Fundamental Analysis & Valuation

FRA:PHI1 • NL0000009538

25.5 EUR
-0.9 (-3.41%)
Last: Mar 5, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This PHI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

PHI1 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 63 industry peers in the Health Care Equipment & Supplies industry. PHI1 has a bad profitability rating. Also its financial health evaluation is rather negative. PHI1 is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. PHI1.DE Profitability Analysis

1.1 Basic Checks

  • PHI1 had positive earnings in the past year.
  • In the past year PHI1 had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
  • Of the past 5 years PHI1 4 years had a positive operating cash flow.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B

1.2 Ratios

  • PHI1 has a Return On Assets of 3.32%. This is comparable to the rest of the industry: PHI1 outperforms 50.79% of its industry peers.
  • PHI1 has a Return On Equity (8.17%) which is in line with its industry peers.
  • Looking at the Return On Invested Capital, with a value of 5.16%, PHI1 is in line with its industry, outperforming 46.03% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for PHI1 is significantly below the industry average of 9.88%.
  • The 3 year average ROIC (3.24%) for PHI1 is below the current ROIC(5.16%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROIC 5.16%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.24%
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 5.02%, PHI1 is in line with its industry, outperforming 49.21% of the companies in the same industry.
  • PHI1's Profit Margin has declined in the last couple of years.
  • PHI1 has a Operating Margin (7.98%) which is in line with its industry peers.
  • In the last couple of years the Operating Margin of PHI1 has declined.
  • PHI1 has a Gross Margin of 45.18%. This is in the lower half of the industry: PHI1 underperforms 73.02% of its industry peers.
  • PHI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
OM growth 3YN/A
OM growth 5Y-5.59%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. PHI1.DE Health Analysis

2.1 Basic Checks

  • PHI1 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for PHI1 has been increased compared to 1 year ago.
  • PHI1 has more shares outstanding than it did 5 years ago.
  • PHI1 has a worse debt/assets ratio than last year.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • The Debt to FCF ratio of PHI1 is 16.37, which is on the high side as it means it would take PHI1, 16.37 years of fcf income to pay off all of its debts.
  • With a Debt to FCF ratio value of 16.37, PHI1 is not doing good in the industry: 61.90% of the companies in the same industry are doing better.
  • PHI1 has a Debt/Equity ratio of 0.63. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
  • PHI1 has a Debt to Equity ratio of 0.63. This is in the lower half of the industry: PHI1 underperforms 68.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Altman-Z N/A
ROIC/WACC0.79
WACC6.49%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

2.3 Liquidity

  • PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
  • PHI1's Current ratio of 1.32 is in line compared to the rest of the industry. PHI1 outperforms 42.86% of its industry peers.
  • A Quick Ratio of 0.94 indicates that PHI1 may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.94, PHI1 is not doing good in the industry: 61.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.94
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PHI1.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 6.11% over the past year.
  • The Earnings Per Share has been decreasing by -6.62% on average over the past years.
  • Looking at the last year, PHI1 shows a decrease in Revenue. The Revenue has decreased by -1.04% in the last year.
  • PHI1 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.59% yearly.
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%

3.2 Future

  • PHI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.42% yearly.
  • The Revenue is expected to grow by 3.77% on average over the next years.
EPS Next Y3.51%
EPS Next 2Y8.11%
EPS Next 3Y15.73%
EPS Next 5Y8.42%
Revenue Next Year1.71%
Revenue Next 2Y3.03%
Revenue Next 3Y3.53%
Revenue Next 5Y3.77%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. PHI1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 17.35, which indicates a rather expensive current valuation of PHI1.
  • 87.30% of the companies in the same industry are more expensive than PHI1, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 26.69. PHI1 is valued slightly cheaper when compared to this.
  • Based on the Price/Forward Earnings ratio of 16.76, the valuation of PHI1 can be described as correct.
  • PHI1's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PHI1 is cheaper than 68.25% of the companies in the same industry.
  • PHI1 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.79, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 17.35
Fwd PE 16.76
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • PHI1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. PHI1 is cheaper than 71.43% of the companies in the same industry.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as PHI1.
Industry RankSector Rank
P/FCF 49.71
EV/EBITDA 11.71
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • PHI1's earnings are expected to grow with 15.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.94
PEG (5Y)N/A
EPS Next 2Y8.11%
EPS Next 3Y15.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHI1.DE Dividend Analysis

5.1 Amount

  • No dividends for PHI1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHI1.DE Fundamentals: All Metrics, Ratios and Statistics

KONINKLIJKE PHILIPS NV

FRA:PHI1 (3/5/2026, 7:00:00 PM)

25.5

-0.9 (-3.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-06
Inst Owners44.83%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap24.55B
Revenue(TTM)17.83B
Net Income(TTM)895.00M
Analysts73.33
Price Target29.29 (14.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.35
Dividend Growth(5Y)216.55%
DP36.65%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.02%
Min EPS beat(2)3.95%
Max EPS beat(2)14.1%
EPS beat(4)4
Avg EPS beat(4)17.83%
Min EPS beat(4)3.95%
Max EPS beat(4)31.04%
EPS beat(8)4
Avg EPS beat(8)2.84%
EPS beat(12)6
Avg EPS beat(12)6.47%
EPS beat(16)7
Avg EPS beat(16)6.93%
Revenue beat(2)0
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-2.4%
Max Revenue beat(2)-0.86%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)-0.86%
Revenue beat(8)0
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.36%
Revenue beat(16)2
Avg Revenue beat(16)-1.72%
PT rev (1m)8.18%
PT rev (3m)5.91%
EPS NQ rev (1m)-20.3%
EPS NQ rev (3m)-14.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.56%
Revenue NQ rev (1m)2.87%
Revenue NQ rev (3m)2.28%
Revenue NY rev (1m)-0.99%
Revenue NY rev (3m)-1.57%
Valuation
Industry RankSector Rank
PE 17.35
Fwd PE 16.76
P/S 1.38
P/FCF 49.71
P/OCF 21.13
P/B 2.24
P/tB N/A
EV/EBITDA 11.71
EPS(TTM)1.47
EY5.76%
EPS(NY)1.52
Fwd EY5.97%
FCF(TTM)0.51
FCFY2.01%
OCF(TTM)1.21
OCFY4.73%
SpS18.52
BVpS11.38
TBVpS-0.92
PEG (NY)4.94
PEG (5Y)N/A
Graham Number19.4
Profitability
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROCE 7.33%
ROIC 5.16%
ROICexc 6.02%
ROICexgc 20.88%
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
FCFM 2.77%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.24%
ROIC(5y)N/A
ROICexc(3y)3.72%
ROICexc(5y)N/A
ROICexgc(3y)12.84%
ROICexgc(5y)N/A
ROCE(3y)4.62%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-1.31%
ROICexc growth 3YN/A
ROICexc growth 5Y-4.82%
OM growth 3YN/A
OM growth 5Y-5.59%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Debt/EBITDA 2.72
Cap/Depr 59.38%
Cap/Sales 3.75%
Interest Coverage 5.63
Cash Conversion 45.59%
Profit Quality 55.2%
Current Ratio 1.32
Quick Ratio 0.94
Altman-Z N/A
F-Score7
WACC6.49%
ROIC/WACC0.79
Cap/Depr(3y)53.03%
Cap/Depr(5y)53.41%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
EPS Next Y3.51%
EPS Next 2Y8.11%
EPS Next 3Y15.73%
EPS Next 5Y8.42%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%
Revenue Next Year1.71%
Revenue Next 2Y3.03%
Revenue Next 3Y3.53%
Revenue Next 5Y3.77%
EBIT growth 1Y15922.2%
EBIT growth 3YN/A
EBIT growth 5Y-5.03%
EBIT Next Year68.56%
EBIT Next 3Y26.52%
EBIT Next 5Y17.27%
FCF growth 1Y-43.86%
FCF growth 3YN/A
FCF growth 5Y-22.31%
OCF growth 1Y-25.32%
OCF growth 3YN/A
OCF growth 5Y-15.14%

KONINKLIJKE PHILIPS NV / PHI1.DE FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


How profitable is KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 3 / 10.


How financially healthy is KONINKLIJKE PHILIPS NV?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 1 / 10.


Can you provide the dividend sustainability for PHI1 stock?

The dividend rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 0 / 10 and the dividend payout ratio is 36.65%.